干扰素α-2b联合恩替卡韦治疗慢性乙型肝炎患者的效果

Effects of interferon α-2b combined with Entecavir in treatment of chronic hepatitis B

目的:探讨干扰素α-2b联合恩替卡韦治疗慢性乙型肝炎(CHB)患者的效果。方法:选择2018年11月至2020年10月该院收治的100例CHB患者进行前瞻性研究,按照随机数字表法分为观察组和对照组各50例。对照组采用恩替卡韦治疗,观察组在对照组基础上联合干扰素α-2b治疗,两组均连续治疗12个月。比较两组疗效、治疗前后肝功能指标[丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)]水平、T细胞亚群指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平,以及不良反应发生率。结果:治疗12个月后,观察组治疗总有效率为90.00%(45/50),高于对照组的74.00%(37/50),差异有统计学意义(P<0.05);观察组ALT、AST及CD8^(+)水平均低于对照组,CD4^(+)及CD4^(+)/CD8^(+)水平均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:干扰素α-2b联合恩替卡韦治疗CHB患者可提高治疗总有效率,改善肝功能指标及T细胞亚群指标水平,且安全性良好。

Objective: To explore effects of interferon α-2b combined with Entecavir in treatment of chronic hepatitis B(CHB). Methods:A prospective study was conducted on 100 CHB patients admitted to the hospital from November 2018 to October 2020. They were divided into observation group and control group according to the random number table method, 50 cases in each. The control group was treated with Entecavir,while the observation group was treated with interferon α-2b on the basis of that of the control group. Both groups were treated continuously for 12months. The efficacy, the liver function index levels [alanine aminotransferase(ALT), aspartate aminotransferase(AST)], the T cell subset index levels(CD4^(+), CD8^(+), CD4^(+)/CD8^(+)), and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results: After 12 months of treatment, the total effective rate of the observation group was 90.00%(45/50), which was higher than 74.00%(37/50) of the control group, and the difference was statistically significant(P<0.05). The levels of ALT, AST and CD8^(+) in the observation group were lower than those in the control group, the levels of CD4^(+) and CD4^(+)/CD8^(+) were higher than those in the control group, and the differences were statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions:Interferon α-2b combined with Entecavir in the treatment of the CHB patients can improve the total effective rate of treatment, improve the liver function and the T cell subset index levels, and has good safety.